Pyxis Oncology, Inc. (PYXS)

3.23 -2.71% (-0.09)

Over 5Y: -75.5%

2026-08-28
5 10
2022 2023 2024 2025 2026

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q3 '21 — Operating Cash Flow: -7.3M Q3 '21 — Free Cash Flow: -7.3M Q3 '21 — Net Income: -14.2M Q4 '21 — Operating Cash Flow: -12.2M Q4 '21 — Free Cash Flow: -12.2M Q4 '21 — Net Income: -16.8M Q1 '22 — Operating Cash Flow: -27.7M Q1 '22 — Free Cash Flow: -27.8M Q1 '22 — Net Income: -31.4M Q2 '22 — Operating Cash Flow: -23.7M Q2 '22 — Free Cash Flow: -23.8M Q2 '22 — Net Income: -25.6M Q3 '22 — Operating Cash Flow: -20.6M Q3 '22 — Free Cash Flow: -24.8M Q3 '22 — Net Income: -27.7M Q4 '22 — Operating Cash Flow: -17.4M Q4 '22 — Free Cash Flow: -19.2M Q4 '22 — Net Income: -36.1M Q1 '23 — Operating Cash Flow: -26.8M Q1 '23 — Free Cash Flow: -31.2M Q1 '23 — Net Income: -19.2M Q2 '23 — Operating Cash Flow: -11M Q2 '23 — Free Cash Flow: -13.3M Q2 '23 — Net Income: -15.9M Q3 '23 — Operating Cash Flow: -17.6M Q3 '23 — Free Cash Flow: -17.6M Q3 '23 — Net Income: -23M Q4 '23 — Operating Cash Flow: -15.3M Q4 '23 — Free Cash Flow: -15.3M Q4 '23 — Net Income: -15.6M Q1 '24 — Revenue: 16.1M Q1 '24 — Operating Cash Flow: -20.7M Q1 '24 — Free Cash Flow: -20.9M Q1 '24 — Net Income: -3.3M Q2 '24 — Revenue: 0 Q2 '24 — Operating Cash Flow: -3M Q2 '24 — Free Cash Flow: -3M Q2 '24 — Net Income: -17.3M Q3 '24 — Revenue: 0 Q3 '24 — Operating Cash Flow: -14.7M Q3 '24 — Free Cash Flow: -14.7M Q3 '24 — Net Income: -21.2M Q4 '24 — Revenue: 0 Q4 '24 — Operating Cash Flow: -19.3M Q4 '24 — Free Cash Flow: -19.3M Q4 '24 — Net Income: -35.6M Q1 '25 — Revenue: 0 Q1 '25 — Operating Cash Flow: -22.5M Q1 '25 — Net Income: -21.2M Q2 '25 — Revenue: 2.8M Q2 '25 — Operating Cash Flow: -17.3M Q2 '25 — Net Income: -18.4M Q3 '25 — Revenue: 0 Q3 '25 — Operating Cash Flow: -13.3M Q3 '25 — Net Income: -22M Q4 '25 — Revenue: 11M Q4 '25 — Operating Cash Flow: -10.4M Q4 '25 — Free Cash Flow: -10.4M Q4 '25 — Net Income: -18.1M Q1 '26 — Operating Cash Flow: -26M Q1 '26 — Net Income: -23.3M Q2 '26 — Operating Cash Flow: -18.2M Q2 '26 — Net Income: -25.3M -30M -15M 0 15M 30M
Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2025-12-31, reported in USD. The newest fact in the filings is dated 2026-06-30, 61 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

0.6
SBC / sales 85.8%
OE margin -575.9%
Oper. margin -664.6%
Accruals -37.9%
Capex / sales 0.065%
Gross margin 82.8%
EBITDA margin -634.4%
FCF margin -490.1%
OCF margin -490.0%
Profit margin -640.3%
ROA -161.6%
ROCE -335.6%
ROE -775.6%
OCF / EBIT —
ROIC —

4 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

0.5
RPO / sales —
RPO growth —
Segment HHI —

0 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

4.0
ND/EBITDA —
Interest cover -1012.2×
Debt / Eq 0.0×
Debt payback 0.0 yr
Quick ratio 1.3×
Cash runway 0.49 yr
F-score 2.2 pts
Cash / Debt —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

4.4
Sales/sh Y/Y -19.3%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —
Sales CAGR 4Y —
Sales Q/Q —

2 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.